NCT06974058Completed
Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms
Evaluation of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms: A Pragmatic, Interventional Clinical Study.
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 12 May 2025
- Start date
- Jul 2025
- Primary completion date
- Nov 2025
- Lead sponsor
- Liaquat University of Medical & Health Sciences
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06974058
What you commit to
- Study type: Interventional
- Participants enrolled: 15
- From Jul 2025 to the primary completion date, Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of immunosuppressive medications or corticosteroids within the past month.
Other illness
- Hypersensitivity or allergy to quercetin, curcumin, or any component of the supplement (Nasafytol®).
- Severe, uncontrolled chronic illness (e.g., severe heart failure, chronic kidney disease requiring dialysis, severe liver disease).
- Acute illness at the time of screening.
- Significant psychiatric disorder that may interfere with study compliance.
Other
- Regular use of quercetin or curcumin supplements within the last 3 months.
- Use of anticoagulants (e.g., warfarin, heparin, DOACs) due to potential anticoagulant effects of quercetin/curcumin.
- Pregnancy or breastfeeding.
Who the study is looking for
- Age: 18 to 75 years.
- History of confirmed COVID-19 infection at least 6 months prior to the enrollment.
- Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute infection.
- Diagnosis of Long COVID-19 based on WHO criteria.
- Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS).
- At least one symptom scoring between 1-7 on the C19-YRS.
- Stable medical condition: No recent hospitalization (past 3 months) due to acute illness.
- Willing and able to adhere to the study protocol, including follow-up visits, symptom reporting, and compliance with supplementation
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Liaquat University of Medical & Health Sciences (LUMHS) Coordinator of this site? Confirm its status | Jamshoro | Pakistan | Unknown status |
Related publications
- Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study.Pharmaceuticals (Basel) · 2026 · PMID 42653699
This page is information, not medical advice. Discuss any trial with your doctor.